Treatment With OPN-305, a Humanized Anti–Toll-Like Receptor-2 Antibody, Reduces Myocardial Ischemia/Reperfusion Injury in Pigs

Lack of Fibronectin-EDA Promotes Survival and Prevents Adverse Remodeling and Heart Function Deterioration After Myocardial Infarction

(2011) Fatih Arslan et al.   CIRCULATION RESEARCH

Innate immune signaling in cardiac ischemia

(2011) Fatih Arslan et al.   Nature Reviews Cardiology

Endogenous Inflammatory Molecules Engage Toll-Like Receptors in Cardiovascular Disease

(2010) Mihaela G. Ionita et al.   Journal of Innate Immunity

TLR2 and TLR4 in Ischemia Reperfusion Injury

(2010) F. Arslan et al.   MEDIATORS OF INFLAMMATION

Targeting Toll-like receptors: emerging therapeutics?

(2010) Elizabeth J. Hennessy et al.   NATURE REVIEWS DRUG DISCOVERY

Myocardial Ischemia/Reperfusion Injury Is Mediated by Leukocytic Toll-Like Receptor-2 and Reduced by Systemic Administration of a Novel Anti–Toll-Like Receptor-2 Antibody

(2009) Fatih Arslan et al.   CIRCULATION

Association of Leukocyte and Neutrophil Counts With Infarct Size, Left Ventricular Function and Outcomes After Percutaneous Coronary Intervention for ST-Elevation Myocardial Infarction

(2008) Stanley Chia et al.   AMERICAN JOURNAL OF CARDIOLOGY

Toll-like receptor signaling: a critical modulator of cell survival and ischemic injury in the heart

(2008) Wei Chao   AMERICAN JOURNAL OF PHYSIOLOGY-HEART AND CIRCULATORY PHYSIOLOGY

Stimulation of Toll-Like Receptor 2 in Human Platelets Induces a Thromboinflammatory Response Through Activation of Phosphoinositide 3-Kinase

(2008) Price Blair et al.   CIRCULATION RESEARCH

Bridging Innate Immunity and Myocardial Ischemia/Reperfusion Injury: The Search for Therapeutic Targets

(2008) Fatih Arslan et al.   CURRENT PHARMACEUTICAL DESIGN

The immune system and cardiac repair

(2008) N FRANGOGIANNIS   PHARMACOLOGICAL RESEARCH

Reduction of myocardial infarct size by human mesenchymal stem cell conditioned medium

(2008) Leo Timmers et al.   Stem Cell Research